Clinical Software Drove 63% of Veeva's Subscription Growth, Not the Vault CRM Switch
Hypothesis Opus 5 · Research Opus 5 · Writing Opus 5 · Prompt v1.6
Veeva's growth accelerated for a fourth straight quarter, and the part of the business getting credit for it supplied the smaller share. Of the $108m added to subscription revenue in the July quarter, $68m came from research, quality and regulatory products; the commercial side that houses pharma CRM added $40m.
The rest of the acceleration came from implementation work. Professional services grew 24% against subscriptions' 16% and rose to 17.4% of revenue, and gross margin slipped to 75.0%. The raised full-year guide of $3.682-3.687bn implies second-half growth near 13.7%, almost four points below the quarter just reported. Veeva discloses no backlog figure and no price for its AI agents; Salesforce, reporting the same week, disclosed both.
| Ticker | Company | Segment | Trend · 13mo | 30D | 1Y |
|---|---|---|---|---|---|
| The subject · what this brief is about | |||||
VEEV | Veeva Systems | Life Sciences Software & Data | 🌱 Emerging Bull | +35.2% | +3.2% |
| Compared against · context, not the story | |||||
CRM | Salesforce | Customer Experience & CRM | 🔴 Cont. Bear | +33.8% | −0.1% |
IQV | IQVIA | Contract Research & Development | ⚠️ Emerging Bear | +7.5% | +39.7% |
TEAM | Atlassian | Developer Tools & DevOps | 🔴 Cont. Bear | +78.0% | +5.0% |
NOW | ServiceNow | Specialized Enterprise Solutions | 🌱 Emerging Bull | +17.8% | −26.6% |
HUBS | HubSpot | Customer Experience & CRM | 🔴 Cont. Bear | +1.3% | −46.6% |
12-month price & trend
| Ticker | Mkt cap | P/E | P/E fwd | P/S | P/S fwd | P/GP | P/GP fwd | EV/EBITDA | FCF yld |
|---|---|---|---|---|---|---|---|---|---|
VEEV | $45.6B | 45.2x | 31.0x | 13.2x | 12.5x | 17.6x | 16.7x | 32.0x | 3.6% |
CRM | $168.4B | 18.7x | 14.5x | 3.8x | 3.7x | 5.0x | 4.7x | 12.4x | 9.0% |
IQV | $43.0B | 32.2x | 20.2x | 2.5x | 2.5x | 9.7x | 9.4x | 16.3x | 6.1% |
| Ticker | Mkt cap | P/E | P/E fwd | P/S | P/S fwd | P/GP | P/GP fwd | EV/EBITDA | FCF yld |
|---|---|---|---|---|---|---|---|---|---|
TEAM | $44.3B | n/m | 30.6x | 6.7x | 5.9x | 7.9x | 7.0x | 293.0x | 3.0% |
NOW | $132.8B | 79.8x | 31.6x | 9.0x | 8.2x | 12.1x | 11.0x | 39.8x | 3.4% |
HUBS | $12.1B | 83.8x | 17.8x | 3.5x | 3.3x | 4.2x | 4.0x | 40.2x | 6.3% |
Consensus projections
| Ticker | FY2026E | FY2027E | FY2028E | |
|---|---|---|---|---|
VEEV | Revenue | +16.3% | +15.1% | +12.0% |
| EPS | +23.1% | +14.1% | +10.7% | |
CRM | Revenue | +9.3% | +11.1% | +9.4% |
| EPS | +17.4% | +20.2% | +10.4% | |
IQV | Revenue | +7.6% | +5.8% | +5.9% |
| EPS | +9.0% | +11.2% | +12.0% | |
TEAM | Revenue | +24.7% | +15.4% | +14.7% |
| EPS | +55.5% | −0.1% | +21.6% | |
NOW | Revenue | +22.4% | +18.7% | +18.6% |
| EPS | +17.1% | +23.2% | +21.4% | |
HUBS | Revenue | +18.2% | +14.2% | +14.0% |
| EPS | +38.2% | +25.9% | +18.4% |
Forward fiscal years only. Blank means no analyst coverage for that year.
Veeva Systems sells cloud software to drug and device makers only — clinical-trial, regulatory-submission and quality systems on one side, sales-rep customer-relationship management and prescription data on the other. Revenue in the quarter ended 31 July grew 17.6%, the fourth consecutive quarter of acceleration. The composition is the surprise. Of the $108m added to subscription revenue year on year, $68m came from research-and-development and quality products and $40m from the commercial side — 63% of the increase from the clinical and regulatory franchise.
That matters because the story attached to Veeva all year has been commercial: the forced move of pharma customers off the legacy product Veeva hosted on Salesforce's platform onto its own Vault CRM, with the old system scheduled to end on 31 December 2029. The migration is going Veeva's way. It is not yet what is driving the money.
The acceleration arrives with a services bill
Subscription revenues were $766.8m, up 16%. Professional services — implementation and managed work — were $161.2m, up 24%, and rose to 17.4% of total revenue from 16.5% a year earlier. That mix cost more than subscription scale added: gross margin was 75.0%, down about a quarter of a percentage point year on year. Migrating a top-20 biopharma is consulting labor, and the labor is showing up in the growth rate.
Operating income rose 40%, but against a soft base — the year-ago quarter, around the settlement of Veeva's long antitrust fight with IQVIA, carried a 24.8% operating margin. Sequentially, margin eased from 30.9% in the April quarter to 29.6%. Management raised full-year guidance to $3.682-3.687bn, above the roughly $3.65bn consensus, yet the arithmetic of that raise implies second-half revenue growth near 13.7%, almost four points below the quarter just reported.
The CRM wins are conversions
Veeva won Biogen and Regeneron in the quarter, taking it to 12 of the top 20 biopharmas committed to Vault CRM, with two more decisions expected by year-end; management called it the best CRM quarter it has had. Regeneron's global commitment was announced on 25 August, two weeks after Eli Lilly's. These are Veeva's own customers choosing Vault over the alternative rather than new accounts. "We see Veeva maintaining over 70% share in the CRM space, which means we'll continue to execute," Paul Shawah, executive vice president of strategy, told investors on the 26 August call — a defense of position, not a claim of gains.
Salesforce disputes even that. Its Life Sciences Cloud claims more than 140 customers, roughly double a year earlier, naming Novartis, AstraZeneca and Pfizer, and chief revenue officer Miguel Milano has said publicly that Salesforce is gaining share from Veeva.
What is not disclosed
Veeva publishes no calculated billings and no headline remaining-performance-obligation figure, so there is no contracted backlog against which to test the subscription acceleration. Salesforce, reporting days earlier, disclosed current remaining performance obligations of $33.5bn, up 14% in constant currency, and annualized Agentforce revenue above $1.5bn. Veeva's agentic platform, Falcon, has five early adopters and no disclosed price. "We are the rate limiter right now," chief executive Peter Gassner said on the call. "We have to get that product ready, start working with the early adopters, but interest in Falcon is very high." The only priced new product on the call was Aspen, a horizontal CRM at $50 per user per month plus usage overages.
What the market paid
Shares rose 14.3% on 27 August, but about nine points of that was already in after-hours dealing the night before, and the remainder landed inside a broad session in which software stocks rallied hard: Atlassian and HubSpot, with no news of their own, rose 10.3% and 8.2%. Salesforce, on its own record quarter and an Anthropic partnership, rose 22.6%. Over three months Veeva is up 77%, and now trades at 13.2x trailing sales against roughly 9.2x in early May, and 31x forward earnings against consensus that has revenue growth easing from 15% this fiscal year to 12% next.
The beat and the guidance raise are real, and the regulated system-of-record franchise is intact. What the disclosure does not carry is a reason for a multiple that has expanded more than 40% since spring: the acceleration is services-led, the margin comparison is against a settlement-depressed quarter, the company's own guide embeds deceleration, and the AI products investors are paying for have no revenue line, no attach rate and no price.
Two of the top 20 biopharmas will pick a CRM before the year is out. Each decision is either one more conversion Veeva already had, or the first evidence that Milano is right.























































